MiR-122 modulates glutamine (Gln) metabolism both in vitro and in vivo, implicating the therapeutic potential of miR-122 in hepatocellular carcinoma (HCC) that exhibit relatively high GLS levels (Sengupta et al., 2020). This evidence concerns the gene GLS and hepatocellular carcinoma.